HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone

This item is licensed under:Creative Commons Attribution-NonCommercial 4.0 International

Files in This Item:
JDI 12 1272-1277.pdf661.2 kBPDFView/Open
Please use this identifier to cite or link to this item:

Title: Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone
Authors: Cho, Kyu Yong Browse this author
Nakamura, Akinobu Browse this author →KAKEN DB
Omori, Kazuno Browse this author
Takase, Takahiro Browse this author
Miya, Aika Browse this author
Yamamoto, Kohei Browse this author
Nomoto, Hiroshi Browse this author →KAKEN DB
Kameda, Hiraku Browse this author →KAKEN DB
Taneda, Shinji Browse this author
Kurihara, Yoshio Browse this author
Aoki, Shin Browse this author
Atsumi, Tatsuya Browse this author →KAKEN DB
Miyoshi, Hideaki Browse this author →KAKEN DB
Keywords: Fatty liver
Sodium–glucosecotransporter 2 inhibitors
Type 2diabete
Issue Date: 8-Jul-2021
Publisher: John Wiley & Sons
Journal Title: Journal of Diabetes Investigation
Volume: 12
Issue: 7
Start Page: 1272
End Page: 1277
Publisher DOI: 10.1111/jdi.13457
Abstract: Aims/Introduction Sodium?glucose cotransporter 2 inhibitors, as well as thiazolidines, suppress nonalcoholic fatty liver disease (NAFLD); however, few comparative studies have been reported. Dapagliflozin has shown non‐inferiority compared with pioglitazone for glycemic control, and superiority regarding weight reduction in patients with type 2 diabetes. We carried out a secondary analysis for the favorable effects of sodium?glucose cotransporter inhibitors for NAFLD. Materials and Methods In this multicenter, open‐label, prospective, randomized, parallel‐group comparison trial, patients taking pioglitazone for ≥12 weeks were randomly switched to dapagliflozin or continued pioglitazone for a further 24 weeks. The fatty liver index (FLI), consisting of body mass index, triglycerides, waist circumference and γ‐glutamyl transpeptidase, was used for the evaluation of NAFLD. Results A total of 53 participants with NAFLD (27 dapagliflozin; 26 pioglitazone) were included in this analysis. FLI decreased significantly in the dapagliflozin group (48.7 ± 23.4 to 42.1 ± 23.9) compared with the pioglitazone group (49.0 ± 26.1 to 51.1 ± 25.8; P < 0.01). Multiple linear regression analysis showed that the changes in FLI had a significantly positive correlation with changes in glycated hemoglobin (P = 0.03) and insulin level (P < 0.01) in the dapagliflozin group. Conclusion Dapagliflozin might be more beneficial than pioglitazone in patients with NAFLD. Improvements in FLI would be closely related to glycemic control.
Type: article
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 三好 秀明

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 - Hokkaido University